153 related articles for article (PubMed ID: 29518480)
1. Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients.
Tan K; Leong SM; Kee Z; Caramat PV; Teo J; Blanco MVM; Koay ESC; Cheong WK; Soh TI; Yong WP; Pang A
Cancer Lett; 2018 Jun; 423():1-8. PubMed ID: 29518480
[TBL] [Abstract][Full Text] [Related]
2. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
[TBL] [Abstract][Full Text] [Related]
3. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract][Full Text] [Related]
4. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
Chen Q; Xia HW; Ge XJ; Zhang YC; Tang QL; Bi F
Asian Pac J Cancer Prev; 2013; 14(12):7421-6. PubMed ID: 24460313
[TBL] [Abstract][Full Text] [Related]
5. Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Ulivi P; Canale M; Passardi A; Marisi G; Valgiusti M; Frassineti GL; Calistri D; Amadori D; Scarpi E
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361687
[TBL] [Abstract][Full Text] [Related]
6. Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression.
Kawahara H; Watanabe K; Toyama Y; Yanagisawa S; Kobayashi S; Yanaga K
Hepatogastroenterology; 2012 Oct; 59(119):2115-8. PubMed ID: 22328299
[TBL] [Abstract][Full Text] [Related]
7. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
Akkiprik M; Koca S; Uğurlu MÜ; Ekren R; Peker Eyüboğlu İ; Alan Ö; Erzik C; Güllü Amuran G; Telli TA; Güllüoğlu MB; Sezerman U; Yumuk PF
Clin Breast Cancer; 2020 Aug; 20(4):332-343.e3. PubMed ID: 32201164
[TBL] [Abstract][Full Text] [Related]
8. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.
Mostert B; Sieuwerts AM; Bolt-de Vries J; Kraan J; Lalmahomed Z; van Galen A; van der Spoel P; de Weerd V; Ramírez-Moreno R; Smid M; Verhoef C; IJzermans JN; Gratama JW; Sleijfer S; Foekens JA; Martens JW
Mol Oncol; 2015 Apr; 9(4):920-32. PubMed ID: 25655581
[TBL] [Abstract][Full Text] [Related]
9. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
Alunni-Fabbroni M; Majunke L; Trapp EK; Tzschaschel M; Mahner S; Fasching PA; Fehm T; Schneeweiss A; Beck T; Lorenz R; Friedl TWP; Janni W; Rack B;
BMC Cancer; 2018 Feb; 18(1):141. PubMed ID: 29409452
[TBL] [Abstract][Full Text] [Related]
10. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
12. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.
Matsusaka S; Suenaga M; Mishima Y; Kuniyoshi R; Takagi K; Terui Y; Mizunuma N; Hatake K
Cancer Sci; 2011 Jun; 102(6):1188-92. PubMed ID: 21401804
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
16. Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.
Markou A; Zavridou M; Sourvinou I; Yousef G; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Chem; 2016 Jul; 62(7):1002-11. PubMed ID: 27197674
[TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer.
Cohen SJ; Alpaugh RK; Gross S; O'Hara SM; Smirnov DA; Terstappen LW; Allard WJ; Bilbee M; Cheng JD; Hoffman JP; Lewis NL; Pellegrino A; Rogatko A; Sigurdson E; Wang H; Watson JC; Weiner LM; Meropol NJ
Clin Colorectal Cancer; 2006 Jul; 6(2):125-32. PubMed ID: 16945168
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib.
Matsusaka S; Hanna DL; Ning Y; Yang D; Cao S; Berger MD; Miyamoto Y; Suenaga M; Dan S; Mashima T; Seimiya H; Zhang W; Lenz HJ
Cancer Sci; 2020 Feb; 111(2):441-450. PubMed ID: 31821662
[TBL] [Abstract][Full Text] [Related]
19. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
Madhavan D; Zucknick M; Wallwiener M; Cuk K; Modugno C; Scharpff M; Schott S; Heil J; Turchinovich A; Yang R; Benner A; Riethdorf S; Trumpp A; Sohn C; Pantel K; Schneeweiss A; Burwinkel B
Clin Cancer Res; 2012 Nov; 18(21):5972-82. PubMed ID: 22952344
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
